Engineering magnetotactic bacteria MVs to synergize chemotherapy, ferroptosis and immunotherapy for augmented antitumor therapy-Reference-Cited by-同舟云学术

Engineering magnetotactic bacteria MVs to synergize chemotherapy, ferroptosis and immunotherapy for augmented antitumor therapy

Published:2023 Issue:8 Volume:8 Page:1062-1072
ISSN:2055-6756
Container-title:Nanoscale Horizons
language:en
Short-container-title:Nanoscale Horiz.

Author:

Jiang Gexuan¹²,Xiang Zhichu¹,Fang Qiaojun¹²³^ORCID

Affiliation:

1. Laboratory of Theoretical and Computational Nanoscience, CAS Key Laboratory of Nanophotonic Materials and Devices, CAS Key Laboratory of Nanophotonic Materials and Devices, CAS Center for Excellence in Nanoscience, Beijing Key Laboratory of Ambient Particles Health Effects and Prevention Techniques, National Center for Nanoscience and Technology, Beijing 100190, China

2. University of Chinese Academy of Sciences, Beijing 100049, China

3. Sino-Danish Center for Education and Research, Beijing 101408, China

Abstract

A magnetotactic bacteria membrane vesicle-based nanovaccine integrating chemotherapy/immunotherapy/ferroptosis-inducing capability in one, may provide an efficacious treatment option for enhancing tumor synergistic therapy.

Funder

National Key Research and Development Program of China

Chinese Academy of Sciences

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2023/NH/D3NH00061C

Reference50 articles.

1. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study

2. Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells